RU2001107122A - Tpl-2/cot киназа и способы ее применения - Google Patents
Tpl-2/cot киназа и способы ее применения Download PDFInfo
- Publication number
- RU2001107122A RU2001107122A RU2001107122/14A RU2001107122A RU2001107122A RU 2001107122 A RU2001107122 A RU 2001107122A RU 2001107122/14 A RU2001107122/14 A RU 2001107122/14A RU 2001107122 A RU2001107122 A RU 2001107122A RU 2001107122 A RU2001107122 A RU 2001107122A
- Authority
- RU
- Russia
- Prior art keywords
- tpl
- compound
- compounds
- polypeptide
- activity
- Prior art date
Links
- 102100026907 Mitogen-activated protein kinase kinase kinase 8 Human genes 0.000 title claims 73
- 101710164353 Mitogen-activated protein kinase kinase kinase 8 Proteins 0.000 title claims 72
- 150000001875 compounds Chemical class 0.000 claims 68
- 238000000034 method Methods 0.000 claims 58
- 230000000694 effects Effects 0.000 claims 23
- 102100023050 Nuclear factor NF-kappa-B p105 subunit Human genes 0.000 claims 20
- 101710128765 Enhancer of filamentation 1 Proteins 0.000 claims 13
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 13
- 102000003390 tumor necrosis factor Human genes 0.000 claims 13
- 230000001404 mediated effect Effects 0.000 claims 9
- 239000011541 reaction mixture Substances 0.000 claims 8
- 101000979342 Homo sapiens Nuclear factor NF-kappa-B p105 subunit Proteins 0.000 claims 7
- 230000027455 binding Effects 0.000 claims 7
- 239000012634 fragment Substances 0.000 claims 7
- 229920001184 polypeptide Polymers 0.000 claims 7
- 102000004196 processed proteins & peptides Human genes 0.000 claims 7
- 108090000765 processed proteins & peptides Proteins 0.000 claims 7
- 206010061218 Inflammation Diseases 0.000 claims 6
- 230000004054 inflammatory process Effects 0.000 claims 6
- 230000003993 interaction Effects 0.000 claims 6
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 6
- -1 TPL compound Chemical class 0.000 claims 5
- 239000000203 mixture Substances 0.000 claims 5
- 230000019491 signal transduction Effects 0.000 claims 5
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 201000006417 multiple sclerosis Diseases 0.000 claims 4
- 108020004707 nucleic acids Proteins 0.000 claims 4
- 102000039446 nucleic acids Human genes 0.000 claims 4
- 150000007523 nucleic acids Chemical class 0.000 claims 4
- 230000001105 regulatory effect Effects 0.000 claims 4
- 208000035408 type 1 diabetes mellitus 1 Diseases 0.000 claims 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 3
- 108010052419 NF-KappaB Inhibitor alpha Proteins 0.000 claims 3
- 102100039337 NF-kappa-B inhibitor alpha Human genes 0.000 claims 3
- 108700008625 Reporter Genes Proteins 0.000 claims 3
- 150000001412 amines Chemical class 0.000 claims 3
- 230000033228 biological regulation Effects 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 230000001771 impaired effect Effects 0.000 claims 3
- SGKSWXAABLWFHI-UHFFFAOYSA-N methanesulfonic acid;3-pyridin-4-yl-4,5-dihydro-1h-benzo[g]indazole Chemical compound CS(O)(=O)=O.C1=2CCC3=CC=CC=C3C=2NN=C1C1=CC=NC=C1 SGKSWXAABLWFHI-UHFFFAOYSA-N 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 3
- 125000003356 phenylsulfanyl group Chemical group [*]SC1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims 3
- 229910052708 sodium Inorganic materials 0.000 claims 3
- 239000011734 sodium Substances 0.000 claims 3
- 239000000758 substrate Substances 0.000 claims 3
- 230000002103 transcriptional effect Effects 0.000 claims 3
- 101100421131 Caenorhabditis elegans sek-1 gene Proteins 0.000 claims 2
- 102100031480 Dual specificity mitogen-activated protein kinase kinase 1 Human genes 0.000 claims 2
- 101710146526 Dual specificity mitogen-activated protein kinase kinase 1 Proteins 0.000 claims 2
- 102100033457 NF-kappa-B inhibitor beta Human genes 0.000 claims 2
- 101710204094 NF-kappa-B inhibitor beta Proteins 0.000 claims 2
- 108091000080 Phosphotransferase Proteins 0.000 claims 2
- 201000004681 Psoriasis Diseases 0.000 claims 2
- 206010040047 Sepsis Diseases 0.000 claims 2
- 206010052779 Transplant rejections Diseases 0.000 claims 2
- 150000001413 amino acids Chemical group 0.000 claims 2
- 230000004071 biological effect Effects 0.000 claims 2
- 230000008859 change Effects 0.000 claims 2
- 230000002925 chemical effect Effects 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 230000008482 dysregulation Effects 0.000 claims 2
- FKGNPTXBVFRDDM-UHFFFAOYSA-N ethyl 5-oxo-4-(4-phenylsulfanylanilino)-7,8-dihydro-6h-quinoline-3-carboxylate Chemical compound CCOC(=O)C1=CN=C2CCCC(=O)C2=C1NC(C=C1)=CC=C1SC1=CC=CC=C1 FKGNPTXBVFRDDM-UHFFFAOYSA-N 0.000 claims 2
- 230000006698 induction Effects 0.000 claims 2
- 230000000968 intestinal effect Effects 0.000 claims 2
- 150000002894 organic compounds Chemical class 0.000 claims 2
- 102000020233 phosphotransferase Human genes 0.000 claims 2
- 239000000126 substance Substances 0.000 claims 2
- 230000001629 suppression Effects 0.000 claims 2
- DGEZNRSVGBDHLK-UHFFFAOYSA-N [1,10]phenanthroline Chemical compound C1=CN=C2C3=NC=CC=C3C=CC2=C1 DGEZNRSVGBDHLK-UHFFFAOYSA-N 0.000 claims 1
- 230000004913 activation Effects 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 230000006907 apoptotic process Effects 0.000 claims 1
- 150000001720 carbohydrates Chemical class 0.000 claims 1
- 235000014633 carbohydrates Nutrition 0.000 claims 1
- 238000000423 cell based assay Methods 0.000 claims 1
- 230000004663 cell proliferation Effects 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 230000028993 immune response Effects 0.000 claims 1
- 210000000987 immune system Anatomy 0.000 claims 1
- 230000000899 immune system response Effects 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 230000028709 inflammatory response Effects 0.000 claims 1
- 230000003834 intracellular effect Effects 0.000 claims 1
- 150000002632 lipids Chemical class 0.000 claims 1
- 230000026731 phosphorylation Effects 0.000 claims 1
- 238000006366 phosphorylation reaction Methods 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 230000008054 signal transmission Effects 0.000 claims 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/82—Translation products from oncogenes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Wood Science & Technology (AREA)
- Cell Biology (AREA)
- Urology & Nephrology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Diabetes (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- General Engineering & Computer Science (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Oncology (AREA)
- Biophysics (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9817930.2A GB9817930D0 (en) | 1998-08-18 | 1998-08-18 | Pathway |
| GB9817930.2 | 1998-08-18 | ||
| GB9827712.2 | 1998-12-16 | ||
| GBGB9827712.2A GB9827712D0 (en) | 1998-12-16 | 1998-12-16 | Pathway |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2001107122A true RU2001107122A (ru) | 2003-04-20 |
Family
ID=26314223
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2001107122/14A RU2001107122A (ru) | 1998-08-18 | 1999-08-13 | Tpl-2/cot киназа и способы ее применения |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US20020099169A1 (https=) |
| EP (1) | EP1105501A2 (https=) |
| JP (1) | JP4719831B2 (https=) |
| KR (1) | KR20010085407A (https=) |
| CN (1) | CN1323346A (https=) |
| AU (1) | AU767973B2 (https=) |
| BG (1) | BG105345A (https=) |
| BR (1) | BR9913070A (https=) |
| CA (1) | CA2339036A1 (https=) |
| CZ (1) | CZ2001625A3 (https=) |
| HK (1) | HK1041901A1 (https=) |
| HU (1) | HUP0103797A2 (https=) |
| ID (1) | ID28955A (https=) |
| IL (1) | IL141355A0 (https=) |
| MX (1) | MXPA01001747A (https=) |
| NO (1) | NO20010786L (https=) |
| NZ (1) | NZ510313A (https=) |
| PL (1) | PL347137A1 (https=) |
| RU (1) | RU2001107122A (https=) |
| SK (1) | SK2242001A3 (https=) |
| TR (2) | TR200100624T2 (https=) |
| WO (1) | WO2000011191A2 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6660906B1 (en) | 2000-03-08 | 2003-12-09 | Thomas Jefferson University | Tpl2 transgenic knockout mice |
| US7033790B2 (en) | 2001-04-03 | 2006-04-25 | Curagen Corporation | Proteins and nucleic acids encoding same |
| GB0402661D0 (en) * | 2004-02-06 | 2004-03-10 | Medical Res Council | TPL2 and its expression |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5514505A (en) * | 1995-05-15 | 1996-05-07 | Xerox Corporation | Method for obtaining improved image contrast in migration imaging members |
| UA71889C2 (uk) * | 1996-04-02 | 2005-01-17 | Йєда Рісерч Енд Дівелопмент Ко. Лтд. | Модулятори зв'язаного з рецептором tnf фактора (traf), їх одержання та застосування |
-
1999
- 1999-08-13 HU HU0103797A patent/HUP0103797A2/hu unknown
- 1999-08-13 MX MXPA01001747A patent/MXPA01001747A/es unknown
- 1999-08-13 IL IL14135599A patent/IL141355A0/xx unknown
- 1999-08-13 JP JP2000566444A patent/JP4719831B2/ja not_active Expired - Fee Related
- 1999-08-13 PL PL99347137A patent/PL347137A1/xx not_active IP Right Cessation
- 1999-08-13 HK HK02103643.3A patent/HK1041901A1/zh unknown
- 1999-08-13 CN CN99812172A patent/CN1323346A/zh active Pending
- 1999-08-13 AU AU55633/99A patent/AU767973B2/en not_active Ceased
- 1999-08-13 WO PCT/US1999/018543 patent/WO2000011191A2/en not_active Ceased
- 1999-08-13 NZ NZ510313A patent/NZ510313A/en unknown
- 1999-08-13 CZ CZ2001625A patent/CZ2001625A3/cs unknown
- 1999-08-13 EP EP99942203A patent/EP1105501A2/en not_active Withdrawn
- 1999-08-13 SK SK224-2001A patent/SK2242001A3/sk unknown
- 1999-08-13 ID IDW20010645A patent/ID28955A/id unknown
- 1999-08-13 TR TR2001/00624T patent/TR200100624T2/xx unknown
- 1999-08-13 CA CA002339036A patent/CA2339036A1/en not_active Abandoned
- 1999-08-13 KR KR1020017002091A patent/KR20010085407A/ko not_active Abandoned
- 1999-08-13 RU RU2001107122/14A patent/RU2001107122A/ru not_active Application Discontinuation
- 1999-08-13 TR TR2001/03840T patent/TR200103840T2/xx unknown
- 1999-08-13 BR BR9913070-0A patent/BR9913070A/pt not_active IP Right Cessation
- 1999-08-13 US US09/374,579 patent/US20020099169A1/en not_active Abandoned
-
2001
- 2001-02-16 NO NO20010786A patent/NO20010786L/no not_active Application Discontinuation
- 2001-03-15 BG BG105345A patent/BG105345A/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BR9913070A (pt) | 2001-05-08 |
| PL347137A1 (en) | 2002-03-25 |
| KR20010085407A (ko) | 2001-09-07 |
| BG105345A (en) | 2001-12-31 |
| CN1323346A (zh) | 2001-11-21 |
| ID28955A (id) | 2001-07-19 |
| AU767973B2 (en) | 2003-11-27 |
| WO2000011191A3 (en) | 2000-06-08 |
| HUP0103797A2 (hu) | 2003-10-28 |
| HK1041901A1 (zh) | 2002-07-26 |
| CZ2001625A3 (cs) | 2002-02-13 |
| TR200103840T2 (tr) | 2002-06-21 |
| JP2002531058A (ja) | 2002-09-24 |
| TR200100624T2 (tr) | 2001-08-21 |
| NZ510313A (en) | 2003-11-28 |
| EP1105501A2 (en) | 2001-06-13 |
| US20020099169A1 (en) | 2002-07-25 |
| WO2000011191A2 (en) | 2000-03-02 |
| MXPA01001747A (es) | 2003-06-06 |
| IL141355A0 (en) | 2002-03-10 |
| JP4719831B2 (ja) | 2011-07-06 |
| NO20010786D0 (no) | 2001-02-16 |
| SK2242001A3 (en) | 2001-10-08 |
| AU5563399A (en) | 2000-03-14 |
| NO20010786L (no) | 2001-04-17 |
| CA2339036A1 (en) | 2000-03-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Inagaki et al. | Constitutive phosphorylation and nuclear localization of Smad3 are correlated with increased collagen gene transcription in activated hepatic stellate cells | |
| Weilbaecher et al. | Linkage of M-CSF signaling to Mitf, TFE3, and the osteoclast defect in Mitfmi/mi mice | |
| Stein et al. | Eph receptors discriminate specific ligand oligomers to determine alternative signaling complexes, attachment, and assembly responses | |
| Glass et al. | Trkl3 mediates BDNF/NT-3-dependent survival and proliferation in fibroblasts lacking the low affinity NGF receptor | |
| Sugita et al. | α-Latrotoxin receptor CIRL/latrophilin 1 (CL1) defines an unusual family of ubiquitous G-protein-linked receptors: G-protein coupling not required for triggering exocytosis | |
| Ikeda et al. | A sandwich-enzyme immunoassay for the quantification of lipoprotein lipase and hepatic triglyceride lipase in human postheparin plasma using monoclonal antibodies to the corresponding enzymes | |
| Gilbert et al. | Treatment of autoimmune hyperthyroidism in a murine model of Graves’ disease with tumor necrosis factor-family ligand inhibitors suggests a key role for B cell activating factor in disease pathology | |
| US7196169B2 (en) | Isolated post-translationally modified mammalian proteins for monitoring and diagnosing muscle damage | |
| JP2009065977A (ja) | 細胞シグナリングのモジュレーターを同定する方法 | |
| Skeie et al. | Ryanodine receptor antibodies in myasthenia gravis: epitope mapping and effect on calcium release in vitro | |
| JP2561604B2 (ja) | 神経栄養性薬剤、神経成長因子および神経成長因子促進剤の検出方法 | |
| JP2009132715A (ja) | 新規クラスｉｉサイトカイン受容体およびその使用 | |
| US7563586B2 (en) | Method of identifying a modulator of a voltage-gated sodium channel using cells expressing Nav1.8 and p11 | |
| Shen et al. | Activity-and calcineurin-independent nuclear shuttling of NFATc1, but not NFATc3, in adult skeletal muscle fibers | |
| Qiao et al. | Tissue transglutaminase-mediated formation and cleavage of histamine-gliadin complexes: biological effects and implications for celiac disease | |
| AU2002355997A1 (en) | Sodium channel regulators and modulators | |
| RU2001107122A (ru) | Tpl-2/cot киназа и способы ее применения | |
| Dyer et al. | The effect of active serum albumin on PC12 cells: I. Neurite retraction and activation of the phosphoinositide second messenger system | |
| Finkelshtein et al. | Protein tyrosine phosphatases ε and α perform nonredundant roles in osteoclasts | |
| Tempest et al. | The activated human met gene encodes a protein tyrosine kinase | |
| Dovio et al. | Variations along the 24-hour cycle of circulating osteoprotegerin and soluble RANKL: a rhythmometric analysis | |
| AU2002322657A1 (en) | Novel class II cytokine receptors and uses thereof | |
| US20060024729A1 (en) | Mechanosensitive mammalian potassium channels activatable by polyunsaturated fatty acids and the use of said channels in drug screening | |
| Liedtke et al. | Differential activation of PKC-delta and-zeta by alpha 1-adrenergic stimulation in human airway epithelial cells | |
| US20040236075A1 (en) | Novel glass II cytokine receptors, and uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20050309 |